1425945-82-9

Upstream product

• 1425945-81-8 tert-butyl 2-cyano-4-nitrophenylcarbamate 
• 17420-30-3 5-nitroanthranilonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1156096-32-0 tert-butyl 4-amino-2-cyanophenylcarbamate 

Downstream Products

• 1425945-26-1 9-(3-chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carboxamide 
• 1425945-32-9 N-(3-chloro-4-fluorophenyl)-2-(4,5-dihydro-1H-imidazol-2-yl)thiazolo[5,4-f]quinazolin-9-amine 
• 1425945-34-1 methyl 9-(3-chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carbimidate 
• 1425945-84-1 (Z)-6-amino-2-bromo-3-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)benzonitrile 
• 1425945-87-4 9-(3-chloro-4-fluorophenylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile 
• 1425944-92-8 9-(3-chloro-4-fluorophenylamino)-N-(2-morpholinoethyl)thiazolo[5,4-f]quinazoline-2-carboximidamide 
• 1425945-83-0 (Z)-tert-butyl-3-bromo-4-(4-chloro-5H-1,2,3-dithiazol-5-ylideneamino)-2-cyanophenylcarbamate 
• 1425945-60-3 methyl 9-(2-fluoro-4-methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carbimidate 
• 1425945-63-6 methyl 9-(2,4-dichlorophenylamino)thiazolo[5,4-f]quinazoline-2-carbimidate 
• 1425946-10-6 9-(2-fluoro-4-methoxyphenylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile 
• 1425946-13-9 9-(2,4-dichlorophenylamino)thiazolo[5,4-f]quinazoline-2-carbonitrile 

Relevant academic research and scientific papers

An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases

Methyl 9-anilinothiazolo[5,4-f]quinazoline-2-carbimidates 1 (EHT 5372) and 2 (EHT 1610) are strong inhibitors of DYRK's family kinases. The crystal structures of the complex revealed a noncanonical binding mode of compounds 1 and 2 in DYRK2, explaining the remarkable selectivity and potency of these inhibitors. The structural data and comparison presented here provide therefore a template for further improvement of this inhibitor class and for the development of novel inhibitors selectively targeting DYRK kinases.

DYRK1 INHIBITORS AND USES THEREOF

The present invention relates to novel thiazolo[5,4-?]quinazoline compounds and methods that are useful in the amelioration, treatment or control of Down's syndrome or early Alzheimer's disease or in the amelioration, treatment or control of cancers, especially solid tumors. More specifically, the invention relates to DYRK1A and/or DYRK1B inhibitors and to methods for preparing such compounds.